Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Prevention of Contrast-Induced Nephropathy After Cardiovascular Catheterization and Intervention With High-Dose Strong Statin Therapy in Japan ― The PREVENT CINC-J Study ―
Makoto WatanabeKazutaka AonumaToyoaki MuroharaYasuo OkumuraTakeshi MorimotoSadanori OkadaSunao NakamuraShiro UemuraKoichiro KuwaharaTadateru TakayamaNaofumi DoiTamio NakajimaManabu HoriiKenichi IshigamiKazumiki NomotoDaisuke AbeKoji OiwaKentaro TanakaTerumasa KoyamaAkira SatoTomoya UedaTsunenari SoedaYoshihiko SaitoPREVENT CINC-J Investigators
著者情報
ジャーナル オープンアクセス HTML 早期公開
電子付録

論文ID: CJ-21-0869

この記事には本公開記事があります。
詳細
抄録

Background: Previous studies have reported that high-dose strong statin therapy reduces the incidence of contrast-induced nephropathy (CIN) in statin naïve patients; however, the efficacy of high-dose strong statins for preventing CIN in real-world clinical practice remains unclear. The aim of this study was to evaluate the efficacy of strong statin therapy in addition to fluid hydration for preventing CIN after cardiovascular catheterization.

Methods and Results: This prospective, multicenter, randomized controlled trial included 420 patients with chronic kidney disease who underwent cardiovascular catheterization. They were assigned to receive high-dose pitavastatin (4 mg/day × 4 days) on the day before and of the procedure and 2 days after the procedure (Statin group, n=213) or no pitavastatin (Control group, n=207). Isotonic saline hydration combined with a single bolus of sodium bicarbonate (20 mEq) was scheduled for administration to all patients. In the control group, statin therapy was continued at the same dose as that before randomization. CIN was defined as a ≥0.5 mg/dL increase in serum creatinine or ≥25% above baseline at 48 h after contrast exposure. Before randomization, 83% of study participants were receiving statin treatment. The statin group had a higher incidence of CIN than the control group (3.0% vs. 0%, P=0.01). The 12-month rate of major adverse cardiovascular events was similar between the 2 groups.

Conclusions: High-dose pitavastatin increases the incidence of CIN in this study population.

著者関連情報
© 2022, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top